Immunization, Vaccines and Biologicals

Strategic Advisory Group of Experts on Immunization (SAGE) Decade of Vaccines Working Group (established March 2013)

Terms of Reference

The SAGE Working Group (WG) will facilitate a yearly SAGE independent review of the implementation of the Decade of Vaccines’ Global Vaccine Action Plan (GVAP) and assessment of progress.

Specifically, the WG will:

  • review the quality of the data on the GVAP indicators and make recommendations on changes to the formulation of the indicators, operational definitions and/or the processes for data collection;
  • independently evaluate and document progress towards each of the 6 GVAP Strategic Objectives and towards the achievement of the Decade of Vaccines Goals (2011-2020), using the GVAP Monitoring & Evaluation / Accountability Framework;
  • identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed;
  • identify and document best practices;
  • prepare the GVAP implementation annual report to be presented to the SAGE, and thereafter, with SAGE inputs, be submitted for discussion to the WHO January EB meeting, to the WHA and the independent Expert Review Group (iERG) for the UN Secretary General’s Global Strategy for Women’s and Children’s Health .

In its review the WG should take a broad perspective, encompassing the general environment, including the health system context.


SAGE Members

  • Narendra Arora (Chair of the Working Group), Executive director, International Clinical Epidemiology Network, India
  • Yagob Al-Mazrou, Secretary General - Health Services Council of the Kingdom of Saudi Arabia, Saudi Arabia
  • Alejandro Cravioto, Senior Epidemiologist, Global Evaluative Sciences, Seattle, USA (as of February 2015 and previously Chief Scientific Officer , International Vaccine Institute, Seoul Republic of Korea) (SAGE member as of October 2015)


  • Fuqiang Cui, Epidemiology Professor, Deputy Director National Immunization Program, China CDC, China
  • Elizabeth Ferdinand, Associate Lecturer, University of the West Indias – Cave Hill, Barbados (affiliation as of January 2015 and previously Senior Medical Officer of Health and EPI Manager, Barbados)
  • Alan Hinman, Senior Public Health Scientist - Task Force for Global Health, USA
  • Stephen Inglis, Director National Institute Biological Standards & Control, Health Protection Agency, UK
  • Marie-Yvette Madrid, Independent Consultant, Geneva, Switzerland (as of June 2014 to replace Shawn Gilchrist)
  • Amani Mahmoud Mustafa, Project Manager, Sudan Public Health Training Initiative, The Carter Center, Sudan (affiliation as of May 2014 and previously EPI Manager, Ministry of Health, Sudan).
  • Rebecca Martin, Director Global Immunization Division, US CDC, USA
  • Rozina Mistry, Lecturer and Course Director, Aga Kahn University, Pakistan
  • Helen Rees, Executive Director - Reproductive Health Research Unit, University of Witwatersrand, South Africa (former SAGE Chair 2010 - 2013)
  • David Salisbury, Associate Fellow, Centre on Global Health Security, Chatham House, London, UK (affiliation as of January 2014 and previously Director of Immunization, Department of Health, UK and former SAGE Chair 2005 - 2010)
  • Shawn Gilchrist, President S Gilchrist Consulting Services Inc., Canada (resigned from the Working Group May 2014 for personal reasons and replaced by Yvette Madrid)

Secretariat members

  • DoV Secretariat coordinator: WHO, Kamel Senouci
  • Bill & Melinda Gates Foundation: Angela Hwang
  • GAVI Alliance: Peter Hansen
  • National Institute of Allergy and Infectious Diseases: Lee Hall
  • UNICEF Ahmadu Yakubu
  • WHO: Thomas Cherian

Declarations of Interest

All members completed a declaration of interests. Four members reported relevant interests summarized below:

Shawn Gilchrist (resigned May 2014 for personal reasons)
  • As an exclusive source of income, he provides consultancy services to Sanofi, GlaxoSmithKline, IFPMA, Vaccines Europe and PhRMA Japan. This interest was assessed as personal, non-specific and financially significant*.
Alan Hinman
  • Provided trainings for health care workers in Uganda financed by Merck Company Foundation until 2012. This interest was assessed as non-personal, non-specific and financially significant*.
  • His institution receives a policy grant from Novartis to establish a rabies vaccine and immunoglobulin stockpile which is used to cover 10% of his income. This interest was assessed as non-personal, non-specific and financially significant*.
Stephen Inglis
  • Serves as director of the National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency, a not-for-profit, public body whose purpose is to safeguard and enhance public health through the standardisation and control of biologicals used in medicine, engaging with various commercial organizations. This interest was assessed as non-personal, non-specific and financially significant*.
Rozina Mistry
  • Provided consultancy services to Médecins sans Frontières (MSF) to review of MSF routine immunization portfolio until 2012. Currently provides consultancy on the risks associated to NGOs during out breaks and epidemics. This interest was assessed as personal, non-specific and financially significant*.
  • Served as member of GAVI CSO steering committee until 2012. This interest was assessed as personal, non-specific and financially insignificant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

Last updated: 18 September 2015